Third-party payors are all all entities that from May 1, 2015 to July 31, 2021, paid for and/or provided reimbursement for some or all of the purchase price for Restasis for use by their members, employees, insureds, participants, or beneciaries, where such persons purchased the drug in a pharmacy or received Restasis by mail-order prescription, in the following states: Arizona, Arkansas,* California, Colorado, the District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, West Virginia, and Wisconsin.

* Arkansas purchases, payments, and reimbursements for Restasis must have occurred between May 1, 2015 and July 31, 2017.

Excluded from the class are:

Allergan, its officers, directors, employees, subsidiaries, and affiliates; all federal and state government entities except for cities, towns, municipalities, or counties with self-funded prescription drug plans; all persons or entities who purchased Restasis for purposes of resale or directly from Allergan of its affiliates; fully insured health plans, i.e., plans that purchased insurance covering 100 percent of their reimbursement obligations to members; any “flat copay” consumers who purchased Restasis only via a fixed dollar copayment that does not vary on the basis of the drug’s status as brand or generic; PBMs; and all judges assigned to this case and their chambers staff and any members of the judges’ or chambers staff’s immediate families.